drugset
drugset / Trial / NCT03764735

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735 ↗

Phase 3 Completed 452 enrolled Mitotech, SA ORA, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

Timeline

Start
2018-12-06
Primary completion
2019-02-09
Completion
2019-02-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator SkQ1 Other / unclassified — Other

Indications

dry eye syndrome